West Pharma (WST) Q4 2025 earnings review
HVP Components Power the Beat; Portfolio Clean-Up Begins
West Pharma closed 2025 with strong momentum, delivering a double-digit EPS beat (+12.1% YoY) despite a challenging comparison in its device business. The story is defined by a massive divergence: High-Value Product (HVP) Components surged 15.1% organically, driven by GLP-1 demand and biologic upgrades, while HVP Delivery Devices slumped 18.1% due to the roll-off of a prior-year incentive fee. Management is actively pruning the portfolio, announcing the sale of the SmartDose 3.5mL platform to AbbVie (expected close mid-2026), removing a low-margin drag. FY26 guidance projects an acceleration to 5-7% organic growth, signaling the end of the destocking cycle.
🐂 Bull Case
Gross margin expanded 130bps YoY to 37.8%, the highest level of FY25. This was driven by the favourable mix shift toward HVP Components (now 48% of sales), which carry significantly higher margins than standard products or contract manufacturing.
The agreement to sell the SmartDose 3.5mL system to AbbVie is a strategic positive. It removes a capital-intensive, lower-margin asset, allowing West to focus resources on its core high-margin elastomer and component business.
🐻 Bear Case
Contract Manufacturing growth remains anemic at +1.9% organic. While GLP-1 auto-injectors are growing, they are barely offsetting declines in healthcare diagnostic devices. This segment remains a drag on overall growth rates.
HVP Delivery Devices revenue collapsed 18.1% organically. While management flagged the $25M prior-year comp issue, the segment creates noise in the financials and obscures the strength of the core consumables business.
⚖️ Verdict: 🟢
Bullish. The core HVP Components engine is firing on all cylinders (+15% organic), driving margin expansion. The SmartDose divestiture shows management is serious about capital discipline. FY26 guidance suggests the post-COVID hangover is fully resolved.
Key Themes
HVP Components: The Crown Jewel
HVP Components revenue accelerated to $389.8M, up 20.3% reported and 15.1% organically. This segment now represents nearly half of total sales (48%). Growth is fueled by the 'Westar' and 'Envision' product lines, heavily tied to the GLP-1 boom and the industry-wide shift toward higher quality standards (Annex 1). This is the primary driver of the company's profitability beat.
Strategic Divestiture of SmartDose
Management announced the sale of the SmartDose 3.5mL On-Body Delivery System to AbbVie, with a close expected in mid-2026. This generated ~$6M in restructuring/transaction charges in Q4 but is a long-term positive. It signals an exit from a lower-margin, high-complexity hardware business where West lacked a competitive moat, refining the focus on high-volume, high-margin components.
Margin Resiliency
Accelerating. Gross margin hit 37.8% in Q4, up from 36.6% in Q3 and 35.7% in Q2. Adjusted Operating Margin reached 21.4%. The formula is working: as low-margin Contract Manufacturing stays flat and HVP Components grow double-digits, the mix shift naturally lifts corporate profitability.
Contract Manufacturing Lags
While the GLP-1 narrative often includes auto-injectors, the Contract Manufacturing segment grew only 1.9% organically in Q4. Gains in obesity/diabetes devices were largely offset by declines in healthcare diagnostic devices. This segment creates a drag on the company's overall growth profile (HVP Comp is growing 7x faster).
Standard Products Decline
Standard Products (lower margin) declined 1.7% organically. While this helps the margin mix, it indicates that the legacy parts of the business are facing pricing or volume pressure, likely as customers convert to HVP solutions (cannibalization). While net positive for margins, it puts a ceiling on total volume growth.
Free Cash Flow Explosion
Accelerating. Free Cash Flow for FY25 surged 69.6% to $468.9M. This was driven by a $100M+ increase in Operating Cash Flow and a ~$91M reduction in CapEx ($286M in FY25 vs $377M in FY24). The heavy investment cycle appears to be normalizing, boosting shareholder return potential.
Other KPIs
Accelerating. Beat expectations and grew 12.1% YoY. This is significantly faster than the 7.5% revenue growth, demonstrating strong operating leverage and effective share buybacks (share count down ~1% YoY).
Stable/Decelerating sequentially (vs 5.0% in Q3), but this is purely optical. The 24Q4 period included a $25M one-time incentive fee. Excluding that anomaly, underlying volume growth in the core business remains robust.
Accelerating. Up 20.3% reported. This sub-segment is the company's economic engine. Sequential momentum is strong as biopharma customers restock and GLP-1 production ramps up.
Guidance
Accelerating. Implies organic growth of 5-7%, a step up from the 4.3% achieved in FY25. This confirms management's view that the destocking headwinds of 2024-2025 are over.
Accelerating. The midpoint ($8.02) implies 10% YoY growth. This outpaces the top-line guidance, suggesting continued margin expansion or share repurchases.
Stable/Decelerating. Guided range is lower than FY25 actuals ($286M) and significantly below FY24 ($377M). This reduction in capital intensity should continue to support strong Free Cash Flow conversion.
Accelerating. Implies 13-16% YoY growth against a soft 25Q1 comp ($1.45). This sets a strong cadence for the year.
Key Questions
SmartDose Divestiture Economics
Does the sale of SmartDose to AbbVie completely exit West from the wearable injector market, or are there other platforms remaining? What is the expected dilution or accretion to margins post-close?
Contract Manufacturing Strategy
With Contract Manufacturing growth lagging significantly (1.9%) and margins lower than Proprietary Products, what is the strategy to revitalize this segment beyond GLP-1 auto-injectors? Are further divestitures of diagnostic lines possible?
GLP-1 Concentration Risk
GLP-1s are driving both HVP Components and Contract Manufacturing. What percentage of total revenue is now tied to this single therapeutic class, and are we approaching a concentration risk if the obesity market decelerates?